Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
Login My Member Benefits Archives Research Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    ×
  • Subscribe
Enter stock ticker or keyword
×
5 Ways to Beat the Fed (and Crush Inflation)

Email this Article

Send with mail | ahoo instead.
Required Needs to be a valid email
Required Needs to be a valid email
Pfizer Stock Price Will Climb After Merger Despite U.S. Treasury Efforts
http://mney.co/1I40xVo
Required Please enter the correct value.
Twitter

Pfizer Stock Price Will Climb After Merger Despite U.S. Treasury Efforts

By Diane Alter, Contributing Writer, Money Morning • November 20, 2015

View Comments

Start the conversation

Comment on This Story Click here to cancel reply.

Or to contact Money Morning Customer Service, click here.

Your email address will not be published. Required fields are marked *

Some HTML is OK

The Pfizer stock price is up 0.5% today as the U.S. drug giant remains in advanced stages to buy Allergan Plc. (NYSE: AGN). Pfizer Inc. (NYSE: PFE) is pushing forward with the deal despite the best wishes of the U.S. Treasury, which is trying to curb such mergers.

Pfizer is planning to purchase Allergan in a $150 billion transaction that would be the biggest drug deal ever.

Pfizer is prepared to pay as much as $380 per share for the Ireland-domiciled maker of Botox.

In a serious show of commitment, Pfizer is negotiating a 2% to 3% break-up fee payable to Allergan if Pfizer walks away from the deal. The fee could cost $3 billion to $4.5 billion.

Stock market todayA deal could come as early as Monday.

Still, investors are concerned the deal could be delayed due to new U.S. Treasury Department rules.

The new rules released Thursday are intended to make it more difficult for U.S.-based companies to buy a competitor based abroad and locate the combined entity in a low corporate tax rate country. These moves are called "inversions," and they have become extremely popular in recent years.

The deal would be structured in a way that Allergan would be acquiring Pfizer, even though Pfizer would technically be paying a premium for Allergan's shares. Pfizer and Allergan didn't structure the transaction that way as a result of the Treasury's initial letter on inversions. But the strategy may make it easier for Pfizer to achieve an inversion through a deal with Allergan.

Amid the Treasury's new efforts to crack down on tax inversion deals, the Pfizer stock price dropped 3.1% Thursday to $32.29. Allergan shares fell 2.8% to $302.05.

The Treasury last tightened rules on inversions in 2014. That's when AbbVie Inc. (NYSE: ABBV) shelled out a nearly $1.7 billion break-up fee to peer Shire Plc. (Nasdaq ADR: SHPG) when it abandoned its $55 billion merger agreement that would have seen it relocate to Ireland.

The Treasury cannot outright block an inversion deal. But it can reduce the economic benefits that come from one. And additional rule-making could make these deals even more difficult to pull off.

The U.S. government still is working on tighter rules for a corporate tax-avoidance technique known as earnings-stripping and could release them in the coming months. Reducing U.S. corporate tax rates has become a key platform topic among 2016 Republican presidential hopefuls.

Allergan's operations are largely in New Jersey, but its headquarters are technically in Dublin. In contrast to Pfizer's 26.5% tax rate in 2014, Allergan reported an effective tax rate of just 4.8% for the same period. Its tax rate this year is about 15%.

For the Pfizer stock price, lowering its tax rate would be a bullish catalyst. But it's not the only benefit of the deal...

Join the conversation. Click here to jump to comments…

Login
guest
guest
1 Comment
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
Ron Oates
Ron Oates
7 years ago

Kent,
React, if you will, about SUNE's recent price drop. Is this a buying opportunity, or a sign to wait and watch?
Thanks,
Ron

0
Reply
LIVE
Visit Money Morning Live


Latest News

January 19, 2023 • By Money Morning Stock Research Team

These Stocks Could Go To $0

January 9, 2023 • By Money Morning Stock Research Team

The Government Is Pouring $391 Billion Into These Stocks - Buy Now

December 27, 2022 • By Money Morning Staff Reports

6 IPOs in 2023 You Can’t Afford to Miss
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Profit Takeover This Is VWAP Penny Hawk Trading Today Midday Momentum Pump Up the Close
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Night Trader Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Extreme Profit Hunters Profit Revolution Warlock's World Penny Nation Quantum Data Profits Live Trading Alliance Trade The Close Inside Money Trader Expiration Trader Vega Burst Trader Flashpoint Trader Darknet Hyper Momentum Trader

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell My Info

wpDiscuz